#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13488	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2155	617.4	0	.	n	.	0	G206A	SNP	206	206	G	454	454	A	766	A,G,C	418,307,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13488	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2155	617.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1698	1698	T	796	T,C,G	745,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13488	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2155	617.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1432	1432	C	783	C	770	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25058	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3599	689.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1680	1680	A	805	A	775	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25058	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3599	689.8	0	.	n	.	0	C1344T	SNP	1344	1344	C	1687	1687	T	788	T	747	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25058	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3599	689.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2314	2314	C	776	C	751	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25058	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3599	689.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2388	2388	A	731	A,G	716,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25058	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3599	689.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2940	2940	C	788	C,T	753,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	27	1720	folP	852	852	99.88	folP.l15.c4.ctg.1	1600	106.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4440	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3442	127.7	1	SNP	p	S91F	0	.	.	271	273	TCC	574	576	TCC	157;158;158	T;C;C	153;151;151	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4440	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3442	127.7	1	SNP	p	D95N	0	.	.	283	285	GAC	586	588	GAC	154;153;154	G;A;C	147;141;148	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4440	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3442	127.7	1	SNP	p	D95G	0	.	.	283	285	GAC	586	588	GAC	154;153;154	G;A;C	147;141;148	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1346	108.5	0	.	p	.	0	A39T	NONSYN	115	117	GCC	406	408	ACC	155;156;155	A,C;C;C	145,1;151;147	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1346	108.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	604	606	CAC	172;173;175	C;A;C	170;169;173	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1346	108.5	0	.	p	.	0	E117K	NONSYN	349	351	GAA	640	642	AAA	169;165;164	A;A;A,C	165;160;153,1	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1478	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1346	108.5	1	SNP	p	G45D	0	.	.	133	135	GGC	424	426	GGC	147;145;145	G;G;C	142;141;141	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	840	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1200	69.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1621	1623	GCA	138;138;138	G;C;A	133;130;131	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2104	2106	ATT	182;184;183	A;T;T	171;175;175	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	1	SNP	p	D86N	0	.	.	256	258	GAC	574	576	GAC	143;142;143	G;A,T;C	141;135,1;139	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	1	SNP	p	S87R	0	.	.	259	261	AGT	577	579	AGT	147;147;147	A,C;G;T,G	141,1;140;139,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	1	SNP	p	S87W	0	.	.	259	261	AGT	577	579	AGT	147;147;147	A,C;G;T,G	141,1;140;139,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	1	SNP	p	S87I	0	.	.	259	261	AGT	577	579	AGT	147;147;147	A,C;G;T,G	141,1;140;139,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4038	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3006	133.1	1	SNP	p	S88P	0	.	.	262	264	TCC	580	582	TCC	148;149;149	T;C;C	143;142;142	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3758	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2743	135.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1635	1637	GGC	189;186;187	G;G;C	185;181;181	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1218	1220	GCA	189;190;194	G;C;A	181;176;185	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1221	1223	ATC	196;195;195	A;T;C	186;185;186	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1233	1235	GTG	197;199;201	G;T;G	187;191;192	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1233	1235	GTG	197;199;201	G;T;G	187;191;192	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1737	1739	ACC	166;165;163	A,G;C;C	152,2;159;157	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1791	1793	GCG	160;161;163	G;C,G;G	149;131,2;150	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1791	1793	GCG	160;161;163	G;C,G;G	149;131,2;150	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1914	1916	GGT	162;158;158	G;G;T	154;152;148	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1923	1925	GGC	148;148;144	G;G,C;C	140;141,1;137	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3718	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2444	150.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1941	1943	CCG	133;135;136	C,G;C,A;G,C	101,1;122,1;118,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5524	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3189	171.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2014	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1758	113.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	549	549	C	152	C	143	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	753	755	CAA	239;238;240	C;A;A	231;228;229	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	E212S	NONSYN	634	636	GAA	960	962	AGT	207;202;203	A,G;G,A;T	201,1;196,1;193	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	H213D	NONSYN	637	639	CAT	963	965	GAT	205;203;203	G,A;A,G;T	200,1;196,1;199	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	V215D	NONSYN	643	645	GTT	969	971	GAT	199;203;202	G,T,C;A,C;T	194,1,1;195,1;196	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	I218M	NONSYN	652	654	ATC	978	980	ATG	194;190;190	A;T;G,C,A	191;187;182,1,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	H229Y	NONSYN	685	687	CAC	1011	1013	TAC	190;186;185	T,C;A;C	179,1;174;176	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1095	1097	AAG	210;212;210	A;A;G	204;208;203	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2706	porB1b	1047	1047	98.85	porB1b.l6.c4.ctg.1	1693	158.1	1	SNP	p	G120K	0	.	.	358	360	GGC	684	686	GGC	194;193;196	G;G;C	190;188;191	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10512	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4796	216.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2010	2012	CAT	231;232;231	C;A,G;T	226;227,1;226	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1148	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1253	90.8	1	SNP	p	V57M	0	.	.	169	171	GTG	744	746	GTG	221;224;224	G,A;T;G	216,2;215;218	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
